

a.) Amendment to the Specification:

Please amend the paragraph at page 4, lines 18-19 to read as follows.

(1) A method for stabilizing an antibody in a solution, which comprises adding glycine and citric acid to the antibody in a solution.

Please amend the paragraphs starting at page 4, line 24 and ending at page 5, line 4 to read as follows.

(3) A method for suppressing the formation of a soluble association of an antibody in a solution, which comprises adding glycine to the antibody in a solution.

(4) A method for suppressing the formation of a chemically degraded product of an antibody in a solution, which comprises adding citric acid to the antibody in a solution.

Please amend the paragraph at page 14, lines 10-21 to read as follows.

The antibody to which the present invention can be applied may be any antibody, however, specific examples include a monoclonal antibody to ganglioside GD3, a monoclonal antibody to CCR4 and the like. Examples of the monoclonal antibody to ganglioside GD3 include a mouse monoclonal antibody KM-641 (Japanese Patent No. 3006943), a human chimeric antibody KM-871 (Japanese Published unexamined Patent Application No. 304989/93), a human CDR-grafted antibody KM-8871 (WO 01/23432) and the like. Examples of the monoclonal antibody to CCR4 include a human chimeric

antibody KM2760 (WO 01/64754), an anti-CCR4 human CDR-grafted antibody ~~KM8761~~  
KM8760 (WO 03/18635) and the like.

Please amend the paragraph at page 18, lines 8-22 to read as follows.

The preparation of the present invention may comprise a nonionic surfactant in addition to the above-mentioned antibody, glycine and citric acid, and preferred examples include sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene polyoxypropylene glycols, polyoxyethylene hydrogenated castor oils, polyethylene glycol fatty acid ~~ethers~~ esters, glycerine fatty acid esters, sucrose fatty acid esters and the like. Particularly preferred examples include polyoxyethylene sorbitan monolaurate (polysorbate 20), polyoxyethylene sorbitan monooleate (polysorbate 80) and the like. The nonionic surfactant concentration is not particularly limited as long as it is in a pharmaceutically acceptable concentration, but it is preferably at 0.01 to 10 mg/mL, more preferably 0.05 to 1 mg/mL, most preferably 0.1 to 0.3 mg/mL.

Please amend the paragraph at page 29, lines 2-8 to read as follows.

Each of the solution compositions of formulations 12 to 16 shown in Table 6 was prepared, filtered through a filter with a pore size of 0.2  $\mu$ m, and then injected into a glass test tube. The test tube was sealed with a silicon stopper, whereby a sample preparation was prepared. As for an antibody, a human CDR-grafted antibody to CCR4 disclosed in WO 03/18635, ~~KM8761~~ KM8760 was used.

Please amend the paragraph at page 31, lines 10-17 to read as follows.

Each of the solution compositions of formulations 17 to 21 shown in Table 8 was prepared, subjected to aseptic filtration, injected into a glass vial, and then sealed with a rubber stopper and an aluminum cap, whereby a sample preparation was prepared. All these operations were carried out under an aseptic environment. As for an antibody, a human CDR-grafted antibody to CCR4 disclosed in WO 03/18635, ~~KM8761~~ KM8760 as used.

Please amend the paragraph at page 32, lines 12-14 to read as follows.

~~Example 8~~ Example 7 Confirmation of effect on suppressing soluble associations and chemically degraded products (Stability test)

Please amend the paragraph at page 33, line 1 to read as follows.

Flow rate: 1 ~~mL/min~~ mL/min

Please amend the paragraph starting at page 34, line 18 and ending at page 35, line 1 to read as follows.

A solution composition of a formulation 22 shown in Table 10 was prepared, subjected to aseptic filtration, injected into a glass vial, and then sealed with a rubber stopper and an aluminum cap, whereby a sample preparation was prepared. All these operations were carried out under an aseptic environment. As for an antibody, a human CDR-grafted antibody to CCR4 disclosed in WO 03/18635, ~~KM8761~~ KM8760 was used.

Please amend the paragraph at page 35, line 18 to read as follows.

Flow rate: 1 ~~mL/min~~ mL/min